Consistent safety profile with up to five years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Journal of the American Academy of Dermatology | Nov 21, 2021
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open‐label extension phase
Journal of the European Academy of Dermatology and Venereology | Nov 21, 2021
Platelet-rich plasma in facial rejuvenation: A systematic appraisal of the available clinical evidence
Clinical, Cosmetic and Investigational Dermatology | Nov 19, 2021
A variety of information related to Medicine and Health Care. It's all here.
